NPI: 1861418220 · ANNAPOLIS, MD 21401 · Clinical Medical Laboratory · NPI assigned 07/15/2006
Authorized official FREAS, DAMEAN controls 20+ related entities in our dataset. Read more
| Authorized Official | FREAS, DAMEAN (CEO) |
| NPI Enumeration Date | 07/15/2006 |
Other providers sharing the same authorized official: FREAS, DAMEAN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 16,989 | $1.33M |
| 2019 | 31,402 | $1.43M |
| 2020 | 100,265 | $5.02M |
| 2021 | 84,627 | $5.32M |
| 2022 | 91,782 | $6.47M |
| 2023 | 99,130 | $7.65M |
| 2024 | 70,348 | $6.54M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 293,158 | 253,743 | $23.99M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 114,730 | 99,027 | $5.98M |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 13,595 | 12,624 | $1.56M |
| 64483 | 7,935 | 6,396 | $547K | |
| 95886 | 2,172 | 1,912 | $162K | |
| 64484 | 3,454 | 2,815 | $135K | |
| 99215 | Prolong outpt/office vis | 1,358 | 968 | $130K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2,784 | 820 | $130K |
| 95911 | 781 | 710 | $127K | |
| 64636 | 1,636 | 1,186 | $109K | |
| 64494 | 2,173 | 1,767 | $107K | |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | 127 | 125 | $106K |
| 20611 | 3,491 | 2,753 | $85K | |
| 64635 | 1,598 | 1,231 | $56K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 12,582 | 9,950 | $53K |
| 62321 | 1,139 | 938 | $50K | |
| 64493 | 2,257 | 1,835 | $49K | |
| 62323 | 897 | 779 | $38K | |
| 27096 | 994 | 861 | $38K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 8,704 | 7,433 | $33K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 4,207 | 3,657 | $32K |
| 95910 | 178 | 163 | $25K | |
| 20553 | 1,367 | 1,147 | $20K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2,510 | 2,047 | $19K |
| 72275 | 1,045 | 835 | $19K | |
| J7328 | Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | 476 | 191 | $19K |
| 99205 | Prolong outpt/office vis | 74 | 69 | $15K |
| 20610 | 2,311 | 1,785 | $13K | |
| 64495 | 356 | 294 | $12K | |
| 95913 | 42 | 36 | $10K | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 113 | 102 | $9K |
| 95909 | 74 | 73 | $9K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 378 | 125 | $7K |
| 95885 | 126 | 114 | $7K | |
| 90791 | Psychiatric diagnostic evaluation | 185 | 159 | $6K |
| 77002 | 629 | 512 | $6K | |
| 20552 | 324 | 263 | $5K | |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 295 | 202 | $5K |
| 64491 | 84 | 71 | $5K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 504 | 432 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 254 | 163 | $4K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 115 | 89 | $3K |
| 64634 | 39 | 25 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 86 | 37 | $3K |
| 76942 | 39 | 39 | $2K | |
| 64633 | 35 | 25 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 235 | 214 | $1K |
| 64490 | 84 | 71 | $943.99 | |
| 80373 | 208 | 202 | $669.20 | |
| 80365 | 208 | 202 | $669.20 | |
| 96127 | 97 | 83 | $647.91 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 26 | 12 | $617.96 |
| 80346 | 208 | 202 | $607.47 | |
| 64454 | 17 | 14 | $511.05 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 13 | 13 | $463.36 |
| 80361 | 208 | 202 | $435.58 | |
| 80369 | 100 | 95 | $363.16 | |
| 64450 | 25 | 12 | $345.49 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | 14 | $286.04 |
| 80368 | 141 | 135 | $284.00 | |
| 80355 | 141 | 135 | $284.00 | |
| 80366 | 141 | 135 | $281.00 | |
| 80320 | 100 | 95 | $222.48 | |
| 99443 | 15 | 12 | $210.00 | |
| 80305 | 73 | 68 | $171.20 | |
| 80354 | 50 | 49 | $154.00 | |
| 80348 | 50 | 49 | $154.00 | |
| 80372 | 50 | 49 | $154.00 | |
| 80353 | 50 | 49 | $119.70 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 14 | 12 | $109.06 |
| 99441 | 19 | 12 | $2.51 | |
| 80349 | 14 | 13 | $0.00 | |
| 80357 | 14 | 13 | $0.00 | |
| 1101F | 50 | 48 | $0.00 | |
| 80359 | 14 | 13 | $0.00 | |
| 80324 | 14 | 13 | $0.00 | |
| 1036F | 54 | 52 | $0.00 | |
| 1006F | 71 | 69 | $0.00 | |
| 80345 | 14 | 13 | $0.00 | |
| 84311 | 14 | 13 | $0.00 | |
| 80367 | 14 | 13 | $0.00 | |
| 83986 | 14 | 13 | $0.00 | |
| 80358 | 14 | 13 | $0.00 | |
| 83789 | 14 | 13 | $0.00 | |
| 99442 | 30 | 27 | $0.00 | |
| 82542 | 14 | 13 | $0.00 | |
| 80356 | 14 | 13 | $0.00 | |
| G9365 | One high-risk medication ordered | 60 | 58 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 114 | 108 | $0.00 |
| 81002 | 14 | 13 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 51 | 49 | $0.00 |
| 82570 | 14 | 13 | $0.00 | |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 115 | 109 | $0.00 |
| 0518F | 59 | 57 | $0.00 | |
| 83992 | 14 | 13 | $0.00 | |
| 80360 | 14 | 13 | $0.00 | |
| 80362 | 14 | 13 | $0.00 |